FGF19 and Hyperglycemia: This trial indicated that the dysfunction of β-cell or islet is the predominant factor in hyperglycemia that cannot be corrected by weight loss, which is consistent with our study that the relationship between FGF19 and diabetes was to a small degree moderated by BMI reduction.